Cochrane · systematic review · CD013774
Immunotherapy for advanced or metastatic urothelial carcinoma
Maisch, P, Hwang, EC, Kim, K, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 16.7%Very low 1 · 8.3%Low 5 · 41.7%Moderate 4 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Immune checkpoint inhibitors compared to any first‐line chemotherapy for advanced or metastatic urothelial carcinoma
Population: participants with advanced or metastatic muscle invasive bladder cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to death from any cause Range of Immune checkpoint inhibitors vs any first‐line chemotherapy | HR 0.97 [0.87, 1.07] | 3 studies · 2068 participants | Moderate Downgraded: risk of bias |
Health‐related quality of life Immune checkpoint inhibitors vs any first‐line chemotherapy | no estimate extracted | 1 study · 393 participants | Moderate Downgraded: risk of bias |
Adverse events grade 3 to 5 Range of Immune checkpoint inhibitors vs any first‐line chemotherapy | RR 0.47 [0.29, 0.75] | 3 studies · 2046 participants | Moderate Downgraded: risk of bias |
Time to death from bladder cancer Immune checkpoint inhibitors vs any first‐line chemotherapy | no estimate extracted | 0 studies · 0 participants | Ungraded |
Time to disease progression Range of Immune checkpoint inhibitors vs any first‐line chemotherapy | HR 1.33 [1.17, 1.5] | 2 studies · 1349 participants | Moderate Downgraded: risk of bias |
Discontinuation due to adverse events Range of Immune checkpoint inhibitors vs any first‐line chemotherapy | RR 0.47 [0.2, 1.1] | 3 studies · 2046 participants | Low Downgraded: risk of bias, imprecision |
Immune checkpoint inhibitors compared to any second‐line chemotherapy for advanced or metastatic urothelial carcinoma
Population: participants with advanced or metastatic muscle invasive bladder cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to death from any cause Range of Immune checkpoint inhibitors vs any second‐line chemotherapy | HR 0.72 [0.63, 0.81] | 2 studies · 1473 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life Immune checkpoint inhibitors vs any second‐line chemotherapy | no estimate extracted | 2 studies · 727 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events grade 3 to 5 Range of Immune checkpoint inhibitors vs any second‐line chemotherapy | RR 0.89 [0.81, 0.97] | 2 studies · 1423 participants | Low Downgraded: risk of bias, imprecision |
Time to death from bladder cancer Immune checkpoint inhibitors vs any second‐line chemotherapy | no estimate extracted | 0 studies · 0 participants | Ungraded |
Time to disease progression Range of Immune checkpoint inhibitors vs any second‐line chemotherapy | HR 0.99 [0.84, 1.16] | 2 studies · 1473 participants | Very low Downgraded: risk of bias, imprecision |
Discontinuation due to adverse events Range of Immune checkpoint inhibitors vs any second‐line chemotherapy | RR 0.35 [0.17, 0.72] | 2 studies · 1473 participants | Low Downgraded: risk of bias, imprecision, inconsistency |